Reprogramming tumor network resilience: chemical biology, nanomedicine, and intelligent oncology for clinical translation.
Abstract
BACKGROUND: The dynamic interactions between the signaling networks, the intracellular organelles and the tumor microenvironment (TME) are increasingly recognized to be a systems-level phenomenon in the development of resistance to cancer. Individual molecule and pathway levels signaling, rewiring have failed to cure the clinical disease with compensatory measures. PURPOSE: This review proposes an integrated framework for understanding cancer as a network-mediated disease, shaped by intra-organelle communication and microenvironmental cues, and examines how this systems-level view can inform the design of more effective therapeutic strategies. METHOD: This review provides an integrated approach to cancer as a network mediated disease controlled by intra-organelle communication and microenvironmental signals. Therapeutic sensitivity or resistance is highlighted by key molecular relay systems as ROS-mediated signaling, unfolded protein response (UPR), calcium flux and autophagy-apoptosis. Nanomedicine as systems-level modulator that controls these networks by stimulus responsive therapeutic release, through intracellular trafficking and organelle specific targeting through controlled drug delivery. Emerging nanomedicine strategies designed to modulate resistance-associated pathways are discussed alongside evidence from preclinical studies and established nanomedicine applications, with particular attention to intracellular delivery, organelle targeting, and stimulus-responsive therapeutic release. In addition, modern computational oncology, including network pharmacology, machine learning, and multi-omics, is analyzed for the use in predictive modelling of tumor adaptation and rational design of multi-target drugs. CONCLUSION: This review provides a roadmap for taking systems-level therapeutic strategies to clinical practice by offering an overview of the advances in molecular medicine, drug delivery, and computational oncology. Hence, this review highlights the urgency of transition from reducing strategies towards adaptive strategies for tumour network resilience, and addressing MDTs.
Abstract as supplied by the indexing source. © the authors / publisher.